From connectors and containers to plasmids and platforms, companies work to get these treatments to patients faster and more ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

New research explores how virus-specific T-cell therapy may help prevent or treat cytomegalovirus after transplant, revealing high response rates in HSCT patients but limited data in solid organ ...

Bacteriophages are vital for addressing antibiotic-resistant bacteria, though phage therapies are currently rare. University of Lisbon researchers recently created a new purification workflow to ...

The U.S. Food and Drug Administration (FDA) approved Kamada's application to manufacture CYTOGAM in May 2023. During the year ...

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

This research, which is the first of its kind, suggests that CMV infection may improve treatment outcomes in melanoma patients receiving less intensive immunotherapy, while also markedly reducing ...

The company's collaboration with BigHat Biosciences utilizes advanced technology to enhance therapeutic antibody development, while positive results from their Phase 3 trial for Orforglipron ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer. The research, from the group of Professor Sophia Karagiannis at King's ...